izpis_h1_title_alt

Structural fine-tuning of desmuramylpeptide NOD2 agonists defines their in vivo adjuvant activity
ID Guzelj, Samo (Author), ID Nabergoj, Sanja (Author), ID Gobec, Martina (Author), ID Pajk, Stane (Author), ID Weiss, Veronika (Author), ID Slütter, Bram (Author), ID Frkanec, Ruža (Author), ID Štimac, Adela (Author), ID Šket, Primož (Author), ID Plavec, Janez (Author), ID Mlinarič-Raščan, Irena (Author), ID Jakopin, Žiga (Author)

.pdfPDF - Presentation file, Download (7,19 MB)
MD5: C761D8055516517510B13C20225695BB
URLURL - Source URL, Visit https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00644 This link opens in a new window

Abstract
We report on the design, synthesis, and biological evaluation of a series of nucleotide-binding oligomerization-domain-containing protein 2 (NOD2) desmuramylpeptide agonists with improved in vitro and in vivo adjuvant properties. We identified two promising compounds: 68, a potent nanomolar in vitro NOD2 agonist, and the more lipophilic 75, which shows superior adjuvant activity in vivo. Both compounds had immunostimulatory effects on peripheral blood mononuclear cells at the protein and transcriptional levels, and augmented dendritic-cell-mediated activation of T cells, while 75 additionally enhanced the cytotoxic activity of peripheral blood mononuclear cells against malignant cells. The C$_{18}$ lipophilic tail of 75 is identified as a pivotal structural element that confers in vivo adjuvant activity in conjunction with a liposomal delivery system. Accordingly, liposome-encapsulated 75 showed promising adjuvant activity in mice, surpassing that of muramyl dipeptide, while achieving a more balanced Th1/Th2 immune response, thus highlighting its potential as a vaccine adjuvant.

Language:English
Keywords:reaction products, peptides, proteins, cells, organic compounds, toxicity
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2021
Number of pages:Str. 7809-7838
Numbering:Vol. 64, iss. 11
PID:20.500.12556/RUL-141424 This link opens in a new window
UDC:615.4:54
ISSN on article:0022-2623
DOI:10.1021/acs.jmedchem.1c00644 This link opens in a new window
COBISS.SI-ID:64930051 This link opens in a new window
Publication date in RUL:29.09.2022
Views:695
Downloads:222
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of medicinal chemistry
Shortened title:J. med. chem.
Publisher:American Chemical Society
ISSN:0022-2623
COBISS.SI-ID:25763328 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:reakcijski produkti, farmacevtska kemija, peptidi, toksičnost, organske spojine

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:J3-9256
Name:Razvoj agonistov receptorja NOD2 ter dualnih NOD2/TLR7 agonističnih konjugatov kot novih adjuvansov za cepiva

Funder:HRZZ - Croatian Science Foundation
Project number:IP-2018-01-6910
Name:Sinteza supramolekulskih samo-udruženih nanostruktura za izgradnju naprednih funkcionalnih materijala

Funder:ARRS - Slovenian Research Agency
Project number:BI-HR/18-19-001

Funder:HRZZ - Croatian Science Foundation
Funding programme:Bilateral contract

Funder:Other - Other funder or multiple funders
Funding programme:COST
Project number:CA16231
Name:European Network of Vaccine Adjuvants
Acronym:ENOVA

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back